"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

Continue reading Nuvasive (NUVA): Growth in adult stem cells

Nuvasive (NUVA): Growth in adult stem cells originally appeared on BloggingStocks on Fri, 03 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

"The Obama administration is poised to spend a lot of money on infrastructure; one important sector is the the nation's electric power grid and the communications system," notes growth stock advisor Dave Dyer.

In his Dave Dayer's Newsletter, he explains, "Some products will win big, others will get nothing, but one company will get more business regardless of which products win: Quanta Services (NYSE: PWR), the leading electrical contractor in the country.

"Quanta's service business stands ready to expand with the infrastructure buildout no matter which products are selected.

"They do design, installation, maintenance, and repair on just about any type of network infrastructure (electric power, telecom, broadband cable, and gas pipelines.) Their moat against competitors is size. They are the largest in their field and that is in no danger of changing.

Continue reading Power play: Rebuilding the electric power grid

Power play: Rebuilding the electric power grid originally appeared on BloggingStocks on Tue, 10 Feb 2009 12:40:00 EST. Please see our terms for use of feeds.

"The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer.

In The Dave Dyer Newsletter, he explains, "That is why Celgene (NASDAQ: CELG) is an excellent choice in this economy." Here's his look at this "recession-resistant" company.

"Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt. Revlimid is their blockbuster drug with multi-billion dollar potential. It was first approved by the FDA in 2005, and it has many good years of patent protection ahead of it.

"Revlimid delays the onset of progression of deadly diseases -- leprosy and multiple myeloma. No wonder it is worth $6,000 per month. It is a close derivative of their other drug Thalomid. This drug was used by another company about 50 years ago to treat morning sickness in pregnant women and caused numerous birth defects.

"Despite a recession, we believe that demand for its products will remain strong. For example, if you have multiple myeloma, you would probably do just about anything before missing a payment for your monthly dose of Revlimid.

Continue reading Celgene (CELG): Blockbuster potential?

Celgene (CELG): Blockbuster potential? originally appeared on BloggingStocks on Thu, 27 Nov 2008 14:30:00 EST. Please see our terms for use of feeds.

"Stericycle (NASDAQ SRCL) is a near-monopoly in an essential but unglamorous area, making its an excellent investment in an uncertain economy," says growth stock expert Dave Dyer.

In his Dave Dyer's Newsletter, he states, "If you have something that is dangerous, contaminated, or nasty, and you want it to go away safely, you can rely on SRCL, the leader in medical waste."

"I first recommended the stock almost a year ago, but there is so much good news that I thought this would be a good time to recommend it again.

"And while the stock's 12.4% gain since last August is not spectacular, the S&P 500 is down 14.1% over the same time period -- so SRCL has outperformed the market by a wide margin.

"SRCL is North America's largest provider of medical waste services. In fact, if a major customer wants to contract with a single customer for nationwide services, SRCL is the only choice. Even if the market has not really bottomed out, this is an excellent stock to consider because its business is almost entirely immune to economic cycles.

Continue reading Stericycle (SRCL): Medical waste firm attracts insider buying

Stericycle (SRCL): Medical waste firm attracts insider buying originally appeared on BloggingStocks on Mon, 18 Aug 2008 14:30:00 EST. Please see our terms for use of feeds.

"Irish corporate tax rates are among the lowest in the world because the government tends to tax consumption rather than production," explains Dave Dyer, who poins ouot, "Irish corporations enjoy tax rates as low as 10%, and that has to be a competitive advantage in the global market."

In his The Dave Dyer Newsletter, he looks to one favorite Irish firm, Icon (NASDAQ: ICLR), a contract research organization (CROs) which conducts research required for clinical trials for pharmaceutical products.

Dyers notes, "The market for CROs is very strong right now because many extremely profitable drugs will be losing patent protection in the next few years and there is lots of pressure to find some replacements.

"ICON is one of the few CROs capable of providing services on a global basis. This gives them the advantage is of running clinical trials in multiple countries at once. Also, regulators actually prefer worldwide trials because they normally provide more ethnic diversity in the subject population."

Continue reading Luck of the Irish: An Icon (ICLR) in clinical testing

Luck of the Irish: An Icon (ICLR) in clinical testing originally appeared on BloggingStocks on Tue, 29 Jan 2008 13:00:00 EST. Please see our terms for use of feeds.